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Introduction: Avoidance of relapse is the main aim of long-term antipsychotic treatment in schizo-
phrenia, yet how ‘relapse’ is defined in trials is not well-known.
Methods: We conducted a systematic review of definitions of relapse in trials of continuous antipsychotic
treatment compared with discontinuation, intermittent treatment or dose reduction for people with
schizophrenia spectrum disorders.
Trials were identified from previous Cochrane reviews and a new search. The quality of relapse defini-
tions was rated in terms of reliability and clinical relevance and associations between quality of defi-
nitions and trial characteristics and outcome were explored.
Results: We identified 82 reports of 81 trials which employed 54 different definitions of relapse. There
were 33 definitions in the 35 trials published since 1990, with recent trials employing complex defini-
tions often involving alternative criteria. Only ten primary definitions of relapse required the presence of
psychotic symptoms in all cases, and only three specified this in combination with a measure of overall
severity or functional decline. Only two definitions specified a duration longer than two days. Relapse
definitions were rated as showing good reliability in 37 trials, but only seven showed good clinical
relevance. Six trials with definitions that were both reliable and clinically relevant were slightly longer,
but did not differ from remaining trials in other characteristics or overall or relative risk of relapse.
Conclusions: Antipsychotic trials define relapse in numerous different ways, and few definitions
consistently reflect suggested indications of a clinically significant relapse.
© 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Current recommendations for long-term antipsychotic treat-
ment for peoplewith schizophrenia and related disorders are based
on trials that report lower rates of relapse with continuous anti-
psychotic medication compared with alternative strategies such as
discontinuation or intermittent treatment (Leucht et al., 2012).
What constitutes a ‘relapse’ is not straightforward, however, and
previous reviews have highlighted the lack of consensus on how to
define or measure it (Burns et al., 2000; Eisner et al., 2013; Falloon
et al., 1983; Gleeson et al., 2010; Nuechterlein et al., 2006; Olivares
et al., 2013; San et al., 2015). Different criteria may lead to different
estimates of relapse, which may also vary between groups in trials).
B.V. This is an open access article uof antipsychotics, if definitions are broad and likely to include sit-
uations that reflect withdrawal effects of antipsychotics rather than
the re-emergence of an underlying psychotic condition(Dilsaver
and Alessi, 1988).
Two Delphi panel exercises on clinicians’ conceptions of relapse
highlighted the complexity of the issue, but showed agreement that
relapse was typically characterised by recurrence of psychotic
symptoms and significant changes in functioning or behaviour
(Burns et al., 2000; San et al., 2015). Other recommendations
include a minimum duration of seven days, use of criteria based on
rating scales or consumption of health resources and distinguishing
relapses in people who have complete remission from those with
chronic symptoms (Bebbington et al., 2006; Gleeson et al., 2010;
San et al., 2015).
Whereas previous reviews of relapse definitions in research
have focused on observational studies or trials in first episodender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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in the majority of randomised trials that form the evidence base for
current practice. The current review aims to describe the defini-
tions of relapse that have been employed in randomised controlled
trials of antipsychotic maintenance treatment compared with pla-
cebo, intermittent treatment or guided discontinuation or reduc-
tion involving people with schizophrenia or psychosis. The review
was conducted in accordance with the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA) guidelines
(Moher et al., 2009).
2. Methods
2.1. Eligibility criteria
Studies were included if theywere randomised trials involving a
comparison between antipsychotic maintenance treatment and
placebo, gradual antipsychotic withdrawal or reduction or inter-
mittent treatment for people with schizophrenia or schizophrenia-
like psychoses. Included studies had to report ‘relapse’ or a similar
outcome such as ‘deterioration,’ ‘treatment failure’ or hospital-
isation. Studies not published in the Latin based alphabet were
excluded.
2.2. Searches
We assessed the eligibility of all studies included in recent
Cochrane reviews of antipsychotic maintenance treatment (Leucht
et al., 2012) and intermittent antipsychotic treatment (Sampson
et al., 2013). In addition, we conducted an additional search of
MEDLINE, EMBASE and PsycINFO from June 2011 until October
2018 (date of last search) to identify studies published since pub-
lication of the previous reviews. The search employed the following
combination of terms derived from these reviews:(cessation* OR
withdraw* OR discontinu* OR halt* OR stop* OR drug?holiday* OR
drug?free* OR drop-out* OR dropout* OR drop out OR rehospitalis*
OR relaps* OR maintain* OR maintenance* OR recur* OR intermit-
tent*) AND schizophr* OR schizoaff*.
2.3. Data extraction
Data on definitions of relapse, trial characteristics and relapse
rates were extracted. Information on how relapse was assessed was
extracted where documented, including time intervals between
assessments and whether additional assessments were performed
at the time of relapse.
2.4. Analysis and quality rating
The different criteria used to define relapse were tabulated and
definitions used in studies conducted prior to 1990were contrasted
with those used in trials published since this year.
We evaluated the quality of relapse definitions in individual
trials in terms of both reliability and clinical relevance. Trials were
rated as showing good reliability if they: used objective criteria like
hospitalisation, resumption of antipsychotics, precisely specified
rating scale changes or if they provided precise descriptions of
other methods used, such as would be easily replicable. These re-
quirements had to apply to all relapse criteria included in the trial.
The clinical relevance of relapse definitions was based on find-
ings of previous studies of clinicians’ understandings of relapse
which suggest the presence of positive psychotic symptoms and
changes in functioning or behaviour (Burns et al., 2000; San et al.,
2015). Hence relapse criteria were considered clinically relevant if
they specified an increase in positive psychotic symptoms (ac-
cording to any measure) and global, behavioural or functionaldeterioration of at least a moderate degree, measured by rating
scales or clinical evaluation, for all cases of relapse. Trials that
defined relapse solely as hospitalisation or ‘necessary’ hospital-
isation were also included.
Two authors (JM and TS) independently rated trial quality
initially using the above criteria. Discrepancies were resolved by
discussion and consensus to produce final ratings. Trials in which
relapse definitions showed good reliability and clinical relevance
were compared with other trials, exploring differences in year of
publication, sample size, trial duration, number of criteria used in
relapse definitions, reported blinding of assessors, reported phar-
maceutical industry sponsorship and overall risk and relative risk of
relapse. All analyses were conducted using SPSS version 22. To
calculate relative risk, we applied a continuity correction of 0.5 in
order to include data from trials in which there were zero relapses
in one group.
3. Results
Eighty two analyses of 81 trials that provided a definition of
relapse or deterioration were included, involving a total of 11,437
participants (see Fig. 1). Two follow-ups of the same trial cohort
were included as distinct analyses since they employed different
definitions of relapse (Wunderink et al., 2013; Wunderink et al.,
2007).
3.1. Study characteristics
Table 1 summarises the design and characteristics of the
included studies (detailed in the Supplementary information).
Most consisted of placebo-controlled antipsychotic withdrawal
trials. There were a total of eight trials that evaluated intermittent
treatment (one in parallel with placebo-controlled withdrawal),
and 11 fixed or flexible dose reduction studies.
3.2. Definitions of relapse
Among the 82 trial reports, there were a total of 54 different
primary definitions of relapse (see Supplementary information).
Table 2 shows the most common criteria used in in trials published
before and since 1990. Many trials, especially more recent ones,
used combinations of different criteria. There were 25 different
primary definitions of relapse among the 47 trials published before
1990. For the 35 trials published since 1990, there were 33 different
primary definitions. Four trials also provided one or more sec-
ondary definitions of relapse.
Among studies published before 1990, resumption of antipsy-
chotics was the most common criteria, followed by clinician or
assessor judgement. Ten trials provided no account of how relapse
was defined. All trials published from 1990 provided some defini-
tion and definitions were increasingly likely to include criteria
derived from rating scales. Definitions became increasingly com-
plex over time. The mean number of alternative criteria for the
primary definition of relapse across the whole sample of trials was
2.1 (s.d. 2.2), and it was strongly correlated with year of publication
(Spearman’s rho 0.60, p< 0.001). Studies published before 1990
used amean of 1.1 (s.d. 0.80) definitions per study, compared with a
mean of 3.5 (s.d. 2.7) per study for trials published in 1990 or later.
Trials published since 2000 frequently involved four or five alter-
native criteria of relapse; the highest being ten.
No trials distinguished relapses among those participants who
had experienced complete remission from those who had ongoing
symptoms. A total of 16 reports specified a duration of relapse,
although usually only for criteria involving increased symptoms.
The specified minimum duration was 1 to 2 days in fourteen
studies, with only two reports of the same trial specifying a longer
Fig. 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram.
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et al., 2007).
There was considerable variation in the nature of criteria based
on rating scales. The 23 studies that used the Positive and Negative
Syndrome Scale (PANSS) in the primary definition, for example,
used eighteen different sets of PANSS-based criteria (see Supple-
mentary information). Specified levels of change in PANSS total
scores varied from a 10 point increase to a 30 point or 30% increase,
there was variation in individual items specified, and scores
required on those items ranged from 3 (mild) to 6 (severe).
Although 27 trials included criteria specifying an increase in
psychotic symptoms, primary definitions required an increase in at
least one psychotic symptom in all participants defined as relapsed
in only ten studies (12.2% of the total). Seven of these were pub-
lished since 1990. Similarly, many recent studies used the Clinical
Global Impressions (CGI) Severity (eS) or Improvement (eI) scales,
but only three required change on this measure for all participants
defined as relapsing. Moreover, thresholds varied between CGI-S of
3 (mildly ill) to CGI-S of 6 (severely ill) and CGI-I of 6 (much worse).
Apart from hospitalisation, or ‘necessary’ or ‘immanent’hospitalisation, which was the sole primary definition of relapse in
four studies, few of the definitions included evaluations of func-
tioning or behaviour, or other measures that indicate tangible
consequences of deterioration.
3.3. Quality of relapse definitions
In the initial rating exercise, the two raters agreed 93.9% of the
time on reliability and 98.8% on clinical relevance. In the final rat-
ings, 37 trials (45.1%) were rated as showing good reliability of
relapse definition (Table 1), 19 of which were published since 1990
(54.3% of the 35 trials published since 1990). Seven trials (8.5%)
specified definitions of relapse that indicated good clinical rele-
vance, 4 published before 1990 and 3 since. Although ten studies
included an increase in positive symptoms plus a measure of
increased overall severity as a criterion of relapse, only three
applied this definition to all cases of relapse (Chen et al., 2010;
Gaebel et al., 2011; Pietzcker et al., 1993) and one of these trials
specified that it had used ‘liberal’ thresholds, using CGI-S scores of 3
(mildly ill) and PANSS items scores of between 3 (mild) and 5
Table 1
Characteristics of included studies.
Trial characteristic Number of studies (%) Total¼ 82
Design:
Placebo controlled antipsychotic discontinuation 55 (67%)
Intermittent treatment 7 (9%)
Flexible dose reduction 5 (6%)
Fixed dose reduction 6 (7%)
Benzodiazepine substitution 1 (1%)



















Not reported 10 (12%)
Participant diagnoses:
Schizophrenia spectrum disorder 75 (91%)
First episode psychosis 6 (7%)
Mixed psychosis (including affective psychoses) 1 (1%)
Blinding of assessments reported:
Yes 52 (63%)
No 30 (37%)
Pharmaceutical industry funding reported:
Yes 26 (32%)
No 56 (68%)
Quality of relapse definition: reliability
Good 37 (45%)
Poor or unknown 45 (55%)
Quality of relapse definition: clinical relevance
Good 7 (9%)
Poor or unknown 75 (91%)
Trial characteristic Mean (s.d.)
Sample size 139.7 (155.3)
Duration 11.6 (10.9)
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good reliability and clinical relevance of the primary definition of
relapse and four of these used hospitalisation as the sole relapse
criterion (Carpenter et al., 1990; Carpenter et al., 1987; Gaebel et al.,
2011; Hogarty et al., 1974; McCreadie et al., 1989; Pietzcker et al.,
1993).
Comparisons indicated that the six trials with higher quality
relapse definitions were twice as long as other trials (Table 3). There
were no differences in other characteristics. Trials with high quality
relapse definitions did not find different rates of overall relapse or
relative risk of relapse compared with other trials. Trials with
relapse definitions rated as reliable regardless of clinical relevance
did not differ from other trials on trial characteristics or relapse
measures. Trials with high clinical relevance of relapse definitions
with or without high reliability showed a trend towards longer
duration than other trials (t¼ 1.87; p¼ 0.07) and use of fewer
relapse criteria (Wald test p¼ 0.07), but there were no other
differences.3.4. Assessment procedures
The frequency of routine assessments during which measures
used to define relapse were completed was specified in 37 trials. In22 of these, assessments were conducted at least once amonth, and
in 12 they were conducted every two weeks or more. Nineteen
trials specified that additional assessments were done when a
relapse was identified, and some others seem likely to have done
this although it was not described. No publications discussed the
potential difficulties of completing measures that require patient
cooperation and response (like the PANSS) with people who are
unwell.
Where rating scales were used to define relapse, they appear to
have been administered during face to face interviews in all but one
trial, which used a retrospective notes review to identify changes in
PANSS positive item scores (Wunderink et al., 2013).
Among trials that used more than two alternative criteria for
defining relapse and reported on which criteria were most
frequently met, changes in overall rating scale scores, psychosis
item scores and clinical judgement were the most commonly
endorsed criteria, and hospitalisation and suicidal or aggressive
behaviour were less frequently fulfilled (Durgam et al., 2016; Fu
et al., 2015; Kane et al., 2011; Rui et al., 2014; Tandon et al., 2016).
One study reported that most relapses were detected at routine
assessments conducted every two weeks (Beasley et al., 2003). Five
trials specified that ‘prodromal’ or non-psychotic symptoms were
included in the primary definition of relapse (Kane et al., 1979;
Table 2
Definitions of relapse.
Type of definition Published prior to 1990 (n¼ 47) Published 1990 or later (n¼ 35)
Number (%) of studies using
definition as part of primary
definition of relapse
Number (%) of studies requiring this
criteria (for all participants considered
to have relapsed)
Number (%) of studies using





Hospitalisation 6 (13%) 3 (6%) 15 (43%) 0
Resumption or increase in antipsychotics 18 (38%) 10 (21%) 5 (14%) 0
Increase or change in any other type of
treatment (e.g. increased visits, other
drugs, ECT)
6 (13%) 0 5 (14%) 0
Clinical judgement 17 (36%) 13 (28%) 2 (6%) 0
Increase in BPRS total score 0 0 3 (9%) 1 (3%)
Increase in PANSS total score 0 0 12 (34%) 0
Increase in BPRS psychosis factor score 0 0 5 (14%) 3 (9%)
Increase in any PANSS positive items or
other specified items
0 0 20 (57%) 4 (11%)
Changes in CGI-I or CGI-S 0 0 18 (51%) 3 (9%)
Impact on functioning or behaviour 4 (9%) 1 (2%) 4 (11%) 3 (9%)
Increase in any positive symptommeasure
plus measure of overall severity,
functioning or behaviour
0 0 9 (26%) 3 (9%)
Self-harm, suicide or suicidal ideation 0 0 14 (40%) 0
Violence to others or property or
homicidal ideation
0 0 14 (40%) 0
Criteria not reported 11 (23%) e 0 e
ECT electro convulsive therapy; BPRS Brief Psychiatric Rating Scale; PANSS Positive and Negative Syndrome Scale; CGI-I Clinical Global Impressions-Improvement; CGI-S
Clinical Global Impressions-Severity.
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1991; Spohn et al., 1986) and a further nine trials described their
criteria as indicating mild or early deterioration, or ‘immanent’
rather than full-blown relapse (Chen et al., 2010; Correll et al., 2017;
Fleischhacker et al., 2016; Fleischhacker et al., 2014; Fu et al., 2015;




The review reveals that there is considerable variation in the
way that relapse has been defined in trials of long-term antipsy-
chotic treatment in people with schizophrenia or psychosis.
Compared to earlier trials, recent trials are more likely to report
detailed definitions of relapse, and to employ rating scales to
identify relapse in at least some cases. However, as in observational
studies (Olivares et al., 2013) definitions in trials have become even
more variable in the last three decades, as trials employ complex
definitions involving combinations of alternative criteria based on
rating scales and other events. Indeed, since 1990, there are almost
as many definitions as trials. Only one trial (Wang et al., 2010) used
criteria suggested by Csernansky et al, 2002 and three others used
similar criteria but with modifications (Hough et al., 2010; Kramer
et al., 2007; Rui et al., 2014).Table 3
Characteristics of trials with high reliability and clinical relevance of relapse definitions
Trials w
Sample size (median, IQR.) 70.5 (16
Duration (mean, s.d.)* 20.0 (6.
Year of publication (mean, s.d.) 1990.7
Number of alternative relapse criteria (median, IQR) 1.0 (2.0
Pharmaceutical industry funding (%) 16.7%
Blinding of assessors (%) 33.3%
Overall risk of relapse (mean, s.d.) 0.37 (0.
Relative risk of relapse (mean, s.d.) 4.4 (4.0
s.d. standard deviation; IQR interquartile range (medians and IQR are presented for non
* t-test yielded p¼ 0.049.Although use of the BPRS and then the PANSS has become
universal across trials since 2000, the way the scales are used and
the thresholds specified vary widely. This reflects the fact that there
is no generally agreed threshold for change in individual symptoms
or total scores at which a relapse or significant deterioration can be
held to have occurred. An additional source of variation is that the
majority of studies using rating scale-based definitions combined
these with various alternative definitions of relapse, including
clinician judgement, need for additional treatment and suicidal or
aggressive behaviour.
While 45% of studies used relatively objective and reliable
measures of relapse, only 8.5% defined relapse in a clinically rele-
vant manner that would coincide with most clinicians’ views of
what constitutes a relapse (Burns et al., 2000; San et al., 2015). Just
over one in ten studies required that everyonewho relapsed should
show positive psychotic symptoms, but only three combined this
with a measure indicating a significant decline in behaviour,
functioning or global state. Most trials also did not specify a mini-
mum duration of symptoms, and only two analyses, both of the
same study cohort, required that relapse symptoms persisted for at
least 7 days (Wunderink et al., 2013; Wunderink et al., 2007). A
previous study found that almost a third fewer relapses were
identified using a 7-day minimum duration criteria (Linszen et al.,
1994). Moreover, several trials reported that most relapses were
identified through changes in rating scale scores during routine
assessments, and none discussed the practical and ethical problemscompared with other trials.
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pears, therefore, that in many trials some relapses, at least, may
reflect mild and potentially short-lived fluctuations in symptoms
that may not reflect real world understandings of relapse, and
might more accurately be described as ‘deteriorations.’
Recent relapse prevention trials are conducted for approval and
marketing purposes and reflect the lower costs of conducting
placebo-controlled trials versus comparative studies. In these sit-
uations, the focus on milder cases of relapse is understandable
given that the use of placebo has been criticised as being redundant
and unethical, and trial lists therefore wish to avoid the occurrence
of severe relapses (Lawrence et al., 2019). Indeed, several recent
definitions were described as referring to ‘impending,’ rather than
full-blown relapse. However, these trials are presented as relapse
prevention studies, and included in meta-analysis of relapse pre-
vention, yet mild symptom deteriorations are not necessarily reli-
able indicators of relapse. Previous research shows that ‘prodromal’
or early symptoms occur frequently and do not reliably predict
subsequent relapse, although psychotic exacerbations, though
rarer, show better specificity (Gaebel and Riesbeck, 2007). More-
over, increases in non-specific symptoms may include adverse ef-
fects related to antipsychotic withdrawal, such as anxiety and
insomnia (Dilsaver and Alessi, 1988).
Although trials that used higher quality definitions were longer
than other trials, we did not demonstrate that the reliability or
clinical relevance of relapse definitions affected the overall or dif-
ferential risk of relapse detected in the trials. Small numbers of
trials with high quality definitions limited the power of these
comparisons, and lack of detail made it difficult to assess how
definitions were applied in practice, however.
4.2. Further research
Further research is required into how to define relapse in a way
that represents a clinically significant event, as well as how it can
be measured in reliable ways. Other reviews have recommended
the use of rating scales (Gleeson et al., 2010), but previous
research has shown little concordance between clinical ratings of
relapse and those based on measuring scale criteria (Linszen et al.,
1994). Moreover, what constitutes a clinically significant change
in rating scale scores needs clarifying. Leucht et al. examined the
clinical significance of differences in PANSS scores in trials of acute
treatment by comparing them with CGI ratings (Leucht et al.,
2006; Leucht et al., 2005). A change of 33 points or between 40%
and 53% was required to be classified as showing more than a
‘minimal’ level of improvement on the CGI-I (Leucht et al., 2006,
Leucht et al., 2005). If the relationship between the PANSS and
CGI-I is linear, this would imply that most current definitions of
relapse reflect only limited degrees of change. However, the
analysis was not based on trials that were assessing relapse. A
linking analysis of this sort would be useful to identify levels of
change in symptom scores that correspond to clinically significant
degrees of deterioration. Further research is also required into
how to measure changes in functioning and other impacts of
symptom deterioration, to assess the personal and social signifi-
cance of the episode. Questions about the necessary duration of
the deterioration and whether positive symptoms should be
specified in order to exclude non-psychotic antipsychotic with-
drawal effects or other non-specific fluctuations in mental state
also need to be resolved.
There also remains the difficulty of how to administer rating
scales if someone is having a full-blown relapse. An alternative
approach of assessing relapse retrospectively based on information
derived from clinical case notes may be useful to circumvent this
problem. This approach also requires operationalisation of criteria
for relapse, but use of common rating scales is complicated sincethey have been designed for face to face assessments. A method of
this sort was devised for a study of an Early Intervention in psy-
chosis programme and reasonable inter-rater reliability was ach-
ieved (kappa 0.71) (Bebbington et al., 2006). Unblinding of raters
occurred, but this may also occur in face to face assessments. We
suggest there is a need to develop this approach further, using
criteria that reflect a clinical conception of relapse, namely the re-
turn or increase of psychotic symptoms along with significant
deterioration in functioning, behaviour or increased risk, and using
a relevant minimum duration of symptoms to exclude short-lived
fluctuations in mental state.
4.3. Limitations
Exploring how relapse was defined was limited by the level of
detail reported, especially in older studies, and this also constrained
evaluation of the quality of definitions, particularly regarding their
clinical relevance. Subjective criteria like clinician judgement and
objective ones, such as restarting antipsychotics, are likely to be
influenced by local and historical factors that are unlikely to be
recorded. Hence some studies using apparently broad criteria may
have identified more severe cases in practice. Evaluating quality
was also difficult in the many modern trials that use numerous
alternative criteria since there was rarely information about which
criteria had been applied most commonly. We were unable to
explore the effects of definitions including a duration criterion
since so few trials stipulated any duration of relapse symptoms, and
where they did it was usually very short.
4.4. Clinical implications
Recommendations for the long-term treatment of people diag-
nosed with schizophrenia and psychotic disorders are based on
trials whose main outcome is relapse. It is important, therefore, to
understand what is meant by relapse in these studies. It transpires
that there is no single or even common definition, and that the
definitions that have been constructed only rarely reflect, at least
consistently, the sort of situation that clinicians would consider to
be characteristic of relapse in the real world. Implications for
treatment decisions might therefore be different from what is
presently understood.
Supplementary data to this article can be found online at
https://doi.org/10.1016/j.schres.2019.08.035.
Funding
This article presents independent research funded by the United
Kingdom’s National Institute for Health Research (NIHR) (project
number: RP-PG-0514-20004). The views expressed are those of the
authors and not necessarily those of the National Health Service,
the NIHR or the Department of Health.
Contributors
JM, NC and ML were responsible for the study concept and
design. JM, NC, ML, RC and TS did the searching and data extraction.
JM, NC and TS performed quality ratings and JM conducted the
statistical analysis. JM wrote the first draft of the manuscript. All
authors helped revise it and all accept the final version.
Conflicts of interest
JM is Chief Investigator for the NIHR-funded RADAR (Reserch
into Antipsychotic Discontinuation And Reduction) programme
which includes a trial comparing antipsychotic reduction with
maintenance treatment. Other authors are, or have, been employed
J. Moncrieff et al. / Schizophrenia Research 225 (2020) 47e54 53on the RADAR programme. No authors have any financial conflicts
of interest.Acknowledgements
The authors would like thank Ms. Rebecca Jones, of the Division
of Psychiatry, University College London, for statistical advice, and
the other grant-holders and the associated Patient and Public
Involvement group for useful discussions about the subject.References
Beasley, C.M., Sutton, V.K., Hamilton, S.H., Walker, D.J., Dossenbach, M., Taylor, C.C.,
Alaka, K.J., Bykowski, D., Tollefson, G.D., 2003. A double-blind, randomised,
placebo-controlled trial of olanzapine in the prevention of psychotic relapse.
J. Clin. Psychopharmacol. 23, 582e594.
Bebbington, P.E., Craig, T., Garety, P., Fowler, D., 2006. Remission and relapse in
psychosis: operational definitions based on case-note data. Psychol. Med.
1551e1562.
Burns, T., Fiander, M., Audini, B., 2000. A delphi approach to characterising “relapse”
as used in UK clinical practice. Int. J. Soc. Psychiatry 46, 220e230. https://
doi.org/10.1177/002076400004600308.
Carpenter, W.T., Heinrichs, D.W., Hanlon, T.E., 1987. A comparative trial of phar-
macologic strategies in schizophrenia. Am. J. Psychiatry 144, 1466e1470.
https://doi.org/10.1176/ajp.144.11.1466.
Carpenter, W.T., Hanlon, T.E., Heinrichs, D.W., Summerfelt, A.T., Kirkpatrick, B.,
Levine, J., Buchanan, R.W., 1990. Continuous versus targeted medication in
schizophrenic outpatients: outcome results. Am. J. Psychiatry 147, 1138e1148.
https://doi.org/10.1176/ajp.147.9.1138.
Chen, E.Y.H., Hui, C.L.M., Lam, M.M.L., Chiu, C.P.Y., Law, C.W., Chung, D.W.S., Tso, S.,
Pang, E.P.F., Chan, K.T., Wong, Y.C., Mo, F.Y.M., Chan, K.P.M., Yao, T.J., Hung, S.F.,
Honer, W.G., 2010. Maintenance treatment with quetiapine versus discontinua-
tion after one year of treatment in patients with remitted first episode psychosis:
randomised controlled trial. BMJ 341, 435. https://doi.org/10.1136/bmj.c4024.
Correll, C.U., Kohegyi, E., Zhao, C., Baker, R.A., McQuade, R., Salzman, P.M.,
Sanchez, R., Nyilas, M., Carson, W., 2017. Oral aripiprazole as maintenance
treatment in adolescent schizophrenia: results from a 52-week, randomized,
placebo-controlled withdrawal study. J. Am. Acad. Child Adolesc. Psychiatry 56,
784e792. https://doi.org/10.1016/j.jaac.2017.06.013.
Csernansky, J.G., Mahmoud, R., Brenner, R., 2002. A comparison of risperidone and
haloperidol for the prevention of relapse in patients with schizophrenia. NEJM
346, 16e22.
Dilsaver, S.C., Alessi, N.E., 1988. Antipsychotic withdrawal symptoms: phenome-
nology and pathophysiology. Acta Psychiatr. Scand. 77, 241e246. https://
doi.org/10.1111/j.1600-0447.1988.tb05116.x.
Durgam, S., Earley, W., Li, R., Li, D., Lu, K., Laszlovszky, I., Fleischhacker, W.W.,
Nasrallah, H.A., 2016. Long-term cariprazine treatment for the prevention of
relapse in patients with schizophrenia: a randomized, double-blind, placebo-
controlled trial. Schizophr. Res. 176, 264e271. https://doi.org/10.1016/
j.schres.2016.06.030.
Eisner, E., Drake, R., Barrowclough, C., 2013. Assessing early signs of relapse in
psychosis: review and future directions. Clin. Psychol. Rev. 33, 637e653. https://
doi.org/10.1016/j.cpr.2013.04.001.
Falloon, I.R.H., Marshall, G.N., Boyd, J., Razani, J., Wood-Siverio, C., 1983. Relapse in
schizophrenia: a review of the concept and its definitions. Psychol. Med. 13,
469e477.
Fleischhacker, W.W., Sanchez, R., Perry, P.P., Jin, N., Peters-Strickland, T.,
Johnson, B.R., Baker, R.A., Eramo, A., McQuade, R.D., Carson, W.H., Walling, D.,
Kane, J.M., 2014. Aripiprazole once-monthly for treatment of schizophrenia:
double-blind, randomised, non-inferiority study. Br. J. Psychiatry 205, 135e144.
https://doi.org/10.1192/bjp.bp.113.134213.
Fleischhacker, W.W., Hobart, M., Ouyang, J., Forbes, A., Pfister, S., McQuade, R.D.,
Carson, W.H., Sanchez, R., Nyilas, M., Weiller, E., 2016. Efficacy and safety of
brexpiprazole (OPC-34712) as maintenance treatment in adults with schizo-
phrenia: a randomized, double-blind, placebo-controlled study. Int. J. Neuro-
psychopharmacol. 20, pyw076. https://doi.org/10.1093/ijnp/pyw076.
Fu, D.J., Turkoz, I., Bruce Simonson, R., Walling, D.P., Schooler, N.R., Lindenmayer, J.P.,
Canuso, C.M., Alphs, L., 2015. Paliperidone palmitate once-monthly reduces risk
of relapse of psychotic, depressive, and manic symptoms and maintains func-
tioning in a double-blind, randomized study of schizoaffective disorder. J. Clin.
Psychiatry 76, 253e262. https://doi.org/10.4088/JCP.14m09416.
Gaebel, W., Riesbeck, M., 2007. Revisiting the relapse predictive validity of pro-
dromal symptoms in schizophrenia. Schizophr. Res. https://doi.org/10.1016/
j.schres.2007.06.016.
Gaebel, W., Riesbeck, M., W€olwer, W., Klimke, A., Eickhoff, M., von Wilmsdorff, M.,
Lemke, M., Heuser, I., Maier, W., Huff, W., Schmitt, A., Sauer, H., Riedel, M.,
Klingberg, S., K€opcke, W., Ohmann, C., M€oller, H.-J., 2011. Relapse prevention in
first-episode schizophreniadmaintenance vs intermittent drug treatment with
prodrome-based early intervention. J. Clin. Psychiatry 72, 205e218. https://
doi.org/10.4088/JCP.09m05459yel.
Gleeson, J.F.M., Alvarez-Jimenez, M., Cotton, S.M., Parker, A.G., Hetrick, S., 2010.
A systematic review of relapse measurement in randomized controlled trials ofrelapse prevention in first-episode psychosis. Schizophr. Res. 119, 79e88.
https://doi.org/10.1016/j.schres.2010.02.1073.
Hogarty, G.E., Goldberg, S.C., Schooler, N.R., 1974. Drug and sociotherapy in the
aftercare of schizophrenic patients. II. Two year relapse rates. Arch. Gen. Psy-
chiatry. https://doi.org/10.1001/archpsyc.1974.01760170005001.
Hough, D., Gopal, S., Vijapurkar, U., Lim, P., Morozova, M., Eerdekens, M., 2010.
Paliperidone palmitate maintenance treatment in delaying the time-to-relapse
in patients with schizophrenia: a randomized, double-blind, placebo-controlled
study. Schizophr. Res. 116, 107e117. https://doi.org/10.1016/j.schres.2009.10.026.
Kane, J.M., Rifkin, A., Quitkin, F., Nayak, D., Saraf, K., Ramos-lorenzi, J.R., Klein, D.F.,
Sachar, E.J., 1979. Low dose fluphenazine decanoate treatment of schizophrenia
in maintenance. Psychiatry Res. 348, 341e348.
Kane, J.M., Mackle, M., Snow-Adami, L., Zhao, J., Szegedi, A., Panagides, J., 2011.
A randomized placebo-controlled trial of asenapine for the prevention of
relapse of schizophrenia after long-term treatment. J. Clin. Psychiatry 72,
349e355. https://doi.org/10.4088/JCP.10m06306.
Kane, J.M., Sanchez, R., Perry, P.P., Jin, N., Johnson, B.R., Forbes, R.A., McQuade, R.D.,
Carson, W.H., Fleischhacker, W.W., 2012. Aripiprazole intramuscular depot as
maintenance treatment in patients with schizophrenia: a 52-week, multicenter,
randomized, double-blind, placebo-controlled study. J. Clin. Psychiatry 73,
617e624. https://doi.org/10.4088/JCP.11m07530.
Kramer, M., Simpson, G., Maciulis, V., Kushner, S., Vijapurkar, U., Lim, P.,
Eerdekens, M., 2007. Paliperidone extended-release tablets for prevention of
symptom recurrence in patients with schizophrenia: a randomized, double-
blind, placebo-controlled study [Erratum appears in J Clin Psychopharmacol.
2007 Jun;27(3):258] J. Clin. Psychopharmacol. 27, 6e14.
Lawrence, R.E., Appelbaum, P.S., Lieberman, J.A., 2019. Are placebo-controlled, relapse
prevention trials in schizophrenia research still necessary or ethical? JAMA
Psychiatry 76, 673e674. https://doi.org/10.1001/jamapsychiatry.2019.0275.
Leucht, S., Kane, J.M., Kissling, W., Hamann, J., Etschel, E., Engel, R.R., 2005. What
does the PANSS mean? Schizophr. Res. 79, 231e238. https://doi.org/10.1016/
j.schres.2005.04.008.
Leucht, S., Kane, J.M., Etschel, E., Kissling, W., Hamann, J., Engel, R.R., 2006. Linking
the PANSS, BPRS, and CGI: clinical implications. Neuropsychopharmacology 31,
2318e2325. https://doi.org/10.1038/sj.npp.1301147.
Leucht, S., Tardy, M., Komossa, K., Heres, S., Kissling, W., Salanti, G., Davis, J.M., 2012.
Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a
systematic review and meta-analysis. Lancet 379, 2063e2071. https://doi.org/
10.1016/S0140-6736(12)60239-6.
Linszen, D.H., Dingemans, P.M., Lenior, M.E., Annet, M., Scholte, W.F., Does, A.J.W.
Van Der, 1994. Relapse Criteria Perspectives in Schizophrenic Disorders:
Different Instruments, pp. 273e281.
McCreadie, R.G., Wiles, D., Grant, S., Crockett, G.T., Mahmood, Z., Livingston, M.G.,
Watt, J.A., Greene, J.G., Kershaw, P.W., Todd, N.A., 1989. The Scottish first episode
schizophrenia study. VII. Two-year follow-up. Scottish schizophrenia research
group. Acta Psychiatr. Scand. 80, 597e602.
Moher, D., Liberati, A., Tetzlaff, J., Altman, D., The Prisma Group, 2009. The PRISMA
Group. Preferred reporting items for systematic reviews and meta-analyses: the
PRISMA statement. Ann. Intern. Med. 151, 264e269. https://doi.org/10.7326/
0003-4819-151-4-200908180-00135.
Nishikawa, T., Tsuda, A., Tanaka, M., Koga, I., Uchida, Y., 1982. Prophylactic effect of
neuroleptics in symptom-free schizophrenics. Psychopharmacology 77,
301e304.
Nishikawa, T., Tanaka, M., Tsuda, A., Koga, I., Uchida, Y., 1989. Prophylactic effects of
neuroleptics in symptom-free schizophrenics: a comparative dose-response
study of timiperone and sulpiride. Biol. Psychiatry 25, 861e866. https://
doi.org/10.1016/0006-3223(89)90265-5.
Nuechterlein, K.H., Miklowitz, D.J., Ventura, J., Gitlin, M.J., Stoddard, M., Lukoff, D.,
2006. Classifying episodes in schizophrenia and bipolar disorder: criteria for
relapse and remission applied to recent-onset samples. Psychiatry Res. 144,
153e166. https://doi.org/10.1016/j.psychres.2004.04.018.
Olivares, J., Sermon, J., Hemels, M., Schreiner, A., 2013. Definitions and drivers of
relapse in patients with schizophrenia: a systematic literature review. Ann.
General Psychiatry. https://doi.org/10.1186/1744-859X-12-32.
Pietzcker, A., Gaebel, W., K€opcke, W., Linden, M., Müller, P., Müller-Spahn, F.,
Tegeler, J., 1993. Intermittent versus maintenance neuroleptic long-term
treatment in schizophrenia. J. Psychiatr. Res. 27, 321e339.
Rui, Q., Wang, Y., Liang, S., Liu, Y., Wu, Y., Wu, Q., Nuamah, I., Gopal, S., 2014. Relapse
prevention study of paliperidone extended-release tablets in Chinese patients
with schizophrenia. Prog. Neuro-Psychopharmacology Biol. Psychiatry 53,
45e53. https://doi.org/10.1016/j.pnpbp.2014.02.007.
Ruskin, P.E., Nyman, G., 1991. Discontinuation of neuroleptic medication in older,
outpatient schizophrenics: a placebo-controlled, double blind trial. J. Nerv.
Ment. Dis. 179, 212e214.
Sampson, S., Mansour, M., Maayan, N., Soares-Weiser, K., Adams, C.E., 2013, Jul 20.
Intermittent drug techniques for schizophrenia. Cochrane Database Syst. Rev. 7,
CD006196 https://doi.org/10.1002/14651858.CD006196.pub2.
San, L., Serrano, M., Ca~nas, F., Romero, S.L., Sanchez-Cabezudo, A., Villar, M., 2015.
Towards a pragmatic and operational definition of relapse in schizophrenia: a
Delphi consensus approach. Int. J. Psychiatry Clin. Pract. https://doi.org/10.3109/
13651501.2014.1002501.
Spohn, H.E., Coyne, L., Larson, J., Mittleman, F., Spray, J., Hayes, K., 1986. Episodic and
residual thought pathology in chronic schizophrenics: effect of neuroleptics.
Schizophr. Bull. 12, 394e407. https://doi.org/10.1093/schbul/12.3.394.
Tandon, R., Cucchiaro, J., Phillips, D., Hernandez, D., Mao, Y., Pikalov, A., Loebel, A.,
2016. A double-blind, placebo-controlled, randomized withdrawal study of
J. Moncrieff et al. / Schizophrenia Research 225 (2020) 47e5454lurasidone for the maintenance of efficacy in patients with schizophrenia.
J. Psychopharmacol. 30, 69e77. https://doi.org/10.1177/0269881115620460.
Wang, C., Xiang, Y., Cai, Z.-J., Weng, Y., Qj, B., JP, Z., TQ, L., GH, W., SM, W., HY, Z., DF,
C., WK, T., GS, U., Investigators., R.M.T. in S. (RMTS), 2010. Risperidone main-
tenance treatment in schizophrenia: a randomized, controlled trial. Am. J.
Psychiatry.
Weiden, P.J., Manning, R., Wolfgang, C.D., Ryan, J.M., Mancione, L., Han, G.,
Ahmed, S., Mayo, M.G., 2016. A randomized trial of iloperidone for prevention
of relapse in schizophrenia: the REPRIEVE study. CNS Drugs 30, 735e747.
https://doi.org/10.1007/s40263-016-0345-4.Wunderink, L., Niehuis, F.J., Sytema, S., Slooff, C.J., Knegtering, R., Wiersma, D., 2007.
Guided discontinuation versus maintenance treatment in remitted first-episode
psychosis: relapse rates and functional outcome. J. Clin. Psychiatry 68, 654e661.
https://doi.org/10.4088/JCP.v68n0502.
Wunderink, L., Nieboer, R.M., Wiersma, D., Sytema, S., Nienhuis, F.J., 2013. Recovery
in remitted first-episode psychosis at 7 years of follow-up of an early dose
reduction/discontinuation or maintenance treatment strategy long-term
follow-up of a 2-year randomized clinical trial. JAMA Psychiatry 70, 913e920.
https://doi.org/10.1001/jamapsychiatry.2013.19.
